To include your compound in the COVID-19 Resource Center, submit it here.

Aiming to best at the end

Algeta hopes Alpharadin will be preferred in late-stage prostate cancer

Although four new drugs have come to market for castration-resistant prostate cancer since April 2010, Algeta ASA thinks there will be room for its Alpharadin radium-223 chloride to replace taxanes in the sickest patients.

Data from the Phase III ALSYMPCA trial reported this month showed an improvement in overall survival compared to placebo. But Alpharadin's real advantage may be that it provides better quality of life for these end-of-life patients than the taxanes that are current standard of care.

Three of the new drugs are primarily focused on early stage, asymptomatic CRPC.

One of these is Provenge sipuleucel-T, an

Read the full 963 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers